Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

The drug, called AL002, is designed to activate a group of surveilling neuronal immune cells called microglia. It was among ...

Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...

European shares were lower today. The eurozone's STOXX 600 slipped 0.50%, Germany's DAX fell 0.49% and France's CAC 40 ...